Brief: Valbiotis Completes Recruitment In Prediabetes Study

Valbiotis SA

28/07/2022 06:56

July 28 (Reuters) - VALBIOTIS SA  ALVAL.PA :
    * VALBIOTIS ANNOUNCES COMPLETION OF RECRUITMENT FOR PHASE
II/III
REVERSE-IT CLINICAL STUDY WITH TOTUM•63 AGAINST PREDIABETES, IN
PARTNERSHIP WITH NESTLÉ HEALTH SCIENCE
    * PHASE II/III STUDY EVALUATING EFFICACY OF TOTUM•63 IN
POPULATION
WITH IMPAIRED GLUCOSE METABOLISM, FROM PREDIABETES TO UNTREATED
TYPE 2 DIABETES (EARLY STAGE)
    * LAST VOLUNTEER WAS ENROLLED IN REVERSE-IT STUDY;
RECRUITMENT OF
600 PARTICIPANTS IN THIS INTERNATIONAL, MULTICENTER, RANDOMIZED,
PLACEBO-CONTROLLED CLINICAL STUDY IS COMPLETE
    * PRIMARY OBJECTIVE OF STUDY WILL BE REDUCTION OF FASTING
BLOOD
GLUCOSE LEVELS AFTER 24 WEEKS OF TOTUM•63 SUPPLEMENTATION
COMPARED TO PLACEBO
    * RESULTS WILL BE ANNOUNCED AT END OF STUDY
    * PHASE II/III CLINICAL STUDY WAS CO-DESIGNED BY NESTLÉ
HEALTH
SCIENCE, VALBIOTIS, AS PART OF GLOBAL STRATEGIC PARTNERSHIP
BETWEEN TWO COMPANIES ON TOTUM•63

Source text for Eikon:  ID:nBwbH9yHna 
Further company coverage:  ALVAL.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 587 696 600;))